Human coronavirus NL63
|Human coronavirus NL63|
|Group:||Group IV ((+)ssRNA)|
|Species:||Human coronavirus NL63|
Human coronavirus NL63 or HCoV-NL63 is a species of coronavirus that was identified in late 2004 in a seven-month-old child with bronchiolitis in the Netherlands. Infection with the virus has been confirmed worldwide, and has an association with many common symptoms and diseases. Associated diseases include mild to moderate upper respiratory tract infections, severe lower respiratory tract infection, croup and bronchiolitis. The virus is found primarily in young children, the elderly, and immunocompromised patients with acute respiratory illness. It also has a seasonal association in temperate climates. A study performed in Amsterdam estimated the presence of HCoV-NL63 in approximately 4.7% of common respiratory illnesses. Further studies confirmed that the virus is not an emerging virus, but rather one that continually circulates the human population.
Transmission of HCoV-NL63 is likely through droplet expulsion from the respiratory tract, which may be airborne or spread through close personal contact. The virus is able to survive for up to seven days in respiratory secretions and remains infective at room temperature  Once the virus has entered the host it binds to cellular receptors using spike proteins, similar to those found in HIV-1. The virus is able to use Angiotensin-converting enzyme 2 (ACE2) as an entry receptor to bind to and enter target cells. No determination of the specific entry of the virus into the host cell has been completed. Therefore entrance into the cell is either through direct cell fusion with the plasma membrane or endocytosis followed by fusion with the membrane. Due to the lack of a cDNA clone of HCoV-NL63, research on the replication cycle is limited. Because it is a positive single-stranded RNA virus, the processes of replication via transcription and translation can be carried out in the cytoplasm of the infected cell.
The first cases of the infection with HCoV-NL63 were found in young children with severe lower respiratory tract infections admitted to hospitals. While the clinical presentation of the virus can be severe, it has also been found in mild cases of respiratory infection. The comorbidity of HCoV-NL63 with other respiratory infections, has made the specific symptoms of the virus difficult to pinpoint. A study of clinical symptoms in HCoV-NL63 patients without secondary infection, reported the most common symptoms to be fever, cough, rhinitis, sore throat, hoarseness, bronchitis, bronchiolitis, pneumonia, and croup. An early study investigating children with lower respiratory tract illness, found that HCoV-NL63 was more commonly found in outpatients than hospitalized patients, suggesting that it is a common cold virus similar to HCoV-229E and HCoV-OC43, which generally cause less severe symptoms. However, the high frequency of croup is specific to HCoV-NL63 infection.
It is difficult to distinguish between symptoms caused by infection of the HCoV-NL63 virus and those caused by other common human viruses, making diagnosis and detection complex. Reverse transcription polymerase chain reaction of samples collected through nasopharyngeal swab is the most commonly used method for detection of the virus. Viral culture or blood serum testing for antibodies may also be used for the confirmation of infection.
Cause and prevention
It is believed that the route of HCoV-NL63 spread is through direct person-to-person transmission in highly populated areas. The virus can survive for up to a week in outside of the body in aqueous solutions at room temperature and three hours on dry surfaces. Most people will be infected with a coronavirus in their lifetime, but some populations are more susceptible to HCoV-NL63. These population include children under the age of 5, the elderly, and immunocompromised individuals. The virus seems to have seasonal incidence, occurring most frequently in the winter months in temperate climates. In more extreme and tropical climates the virus has no preference toward a particular season. Many studies have reported the co-occurrence of HCoV-NL63 with other human coronavirus, influenza A virus, respiratory syncytial virus (RSV), parainfluenza virus, and human metapneumovirus (hMPV). The Center for Disease Control (CDC) recommends several measures for the prevention of infection with HCoV-NL63 including: washing hands often with soap and water, avoiding close contact with sick individuals, and not touching the eyes, mouth, or nose.
Treatment and prognosis
Treatment for the HCoV-NL63 virus is dependent on the severity of associated symptomology. Most mild to moderate infections will go away on their own. Symptoms can be relieved by taking a pain reliever or fever medication, taking a hot shower, or using a humidifier. Antiviral treatment may be necessary for infected patients that end up in the intensive care unit (ICU) due to acute respiratory infection. Intravenous immunoglobulin is an FDA approved HCoV-NL63 inhibitor that is also used to treat primary immune deficiency, RSV, and Kawasaki disease.
Recent data suggest an association of HCoV-NL63 infection with Kawasaki disease, a systemic vasculitis in childhood that may result in aneurysms of the coronary arteries. In the developed world, Kawasaki disease is the most common cause of acquired heart disease in children. Further analysis of HCoV-NL63 pathogenicity seems warranted, in particular because of recent evidence that this virus uses the same cellular receptor as SARS-CoV (ACE2). HCoV-NL63 has also been found in the intestinal tract of infected individuals and linked to gastroenteritis. This type of infection is the direct result of the viral invasion of the mucosal lining of the intestines. The role of HCoV-NL63 in gastroenteritis is unclear due to typical co-infection with other viruses in this condition. HCoV-NL63 is likely under-detected due its role in many mild to moderate respiratory infections and comorbidity with other disease. Researchers have suggested that more comprehensive, population-based studies are necessary to determine the effects of this virus on systems outside of the respiratory tract.
- Abdul-Rasool, S., & Fielding, B. C. (2010). Understanding Human Coronavirus HCoV-NL63. The Open Virology Journal, 4, 76–84. doi:10.2174/1874357901004010076
- Berkhout, B., Hoek, v. d., L., & Pyrc, K. (2006). Human coronavirus NL63, a new respiratory virus. FEMS Microbiology Reviews, 30(5), 760-773. doi:10.1111/j.1574-6976.2006.00032.x
- Hofmann H, Pyrc K, van der Hoek L, Geier M, Berkhout B & Pohlmann S (2005) Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. Proc Natl Acad Sci USA 102: 7988–7993.
- van der Hoek L & Berkhout B (2005) Questions concerning the New Haven coronavirus. J Infect Dis 192: 350–351.
- Public Health Agency of Canada "Human Coronavirus" Retrieved on July 22, 2015.
- Center for Disease Control "About Coronavirus" Retrieved on July 22, 2015.
- Mayo Clinic "Kawasaki Disease" Retrieved on July 22, 2015
- Fielding, B. (2011). Human coronavirus NL63: A clinically important virus? Future Microbiology, Vol 6 (2), 153-159.